top of page

ASAHI Pharma

By developing new drugs, we provide value beyond the price of medicines for the health of patients and the quality of life of their families, achieve the

happiness of employees, and contribute to our society.

​Company purpose

Our fundamental policy is to provide value beyond the price of medicines for the health of patients and the quality of life of their families based on the needs of patients, rather than economic perspective such as market size. In order to achieve this purpose, the employees of the company, whether they are experienced or young, regardless of their gender or nationality, are all equal and can play their roles to the fullest. By fulfilling the purpose, we make our due contribution to our society.


Our work

Our woek is mainly focused on licensing-in compounds that are strategically discontinued by large pharmaceutical companies, and to complete phase 2 POC (proof of concept) study. Then we will make decision either to out-licensing or to conduct phase 3 studies by ourselves. Through activities above, we will provide value beyond the price of medicines for the health of patients and the quality of life of their families.

Business model

Our business model is to find the best compounds for the best indications and to conduct clinical trials in the best place.

Our definition of the best compounds are those for which Big-Pharma has completed human safety and pharmacology studies in clinical trials, but stopped development due to strategic reasons such as market size. After acquiring the compound, we will conduct POC studies in countries/ regions which have advantageous in clinical trial resources, funds, administrative support and other factors. The best indication is mainly focused on the unmet medical needs of the patient, with compound`s physiological/pathological functions in combination.

By eliminating negative economic impact such as market size, the selection of indications can fully focus on the unmet medical needs of patients and biological effects of the compound. Both increase success possibility in clinical development.

After POC study, we will decide either options. One is to out-licensing the compound and another is to conduct late-stage clinical development and new drug application by ourselves.


Pursuing employee happiness in a vibrant workplace

Asahi Pharma is a company founded by the founder who has been involved in drug discovery and development for over 25 years at a global pharmaceutical company. The motivation for starting the company is to create a place to utilize the expertise and experience that he has accumulated, and for the peoples with the same experiences as well. One of company's objective with priority is to provide a workplace, regardless of age, gender, race or national origin, where they can fully take advantages of their knowledge and expertise.

To achieve this, we use job system with flexibility on work time and position roles such as consultation.

Our strengths

We believe that our success depends on finding right compounds and on securing of funding to support subsequent development. We have advantages in both points.

First, the founding president, who has been engaged in new drug R&D for more than 26 years, co-work with team members that have specialized knowledge in drug development, play a central role in identifying and selecting a right compound.


News about ASAHI Pharma

Use patent application

Nov. 21, 2022

News about ASAHI Pharma

Use patent application

Dec. 25, 2022

News about ASAHI Pharma

We are pleased to announce that we have acquired exclusive worldwide rights to develop and commercialize a compound that has completed clinical 2a.

Jun. 24, 2022


Abraham Lincoln

"The most reliable way to predict the future is to create it."

Contact Form

Contact us to find out more about our business and services.

We look forward to hearing from you.

2-5-1 Azuma, Tsukuba City, Ibaraki 305-0031, Japan

ホーム: お問い合わせ
bottom of page